Methods and compositions for modulating hyperstabilized c-met

Details Methods and compositions for modulating hyperstabilized c-met Methods and compositions for modulating hyperstabilized c-met

2006-03-24

2009-11-10

Zara, Jane (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C435S006120, C436S501000, C530S387900, C530S388100, C530S388150, C530S388220, C536S024310

Reexamination Certificate

active

07615529

ABSTRACT:
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by inhibiting a hyperstabilized c-met protein.

REFERENCES:
patent: 6099841 (2000-08-01), Hillan et al.
patent: 2005/0037431 (2005-02-01), Kirchhofer et al.
patent: 2005/0042216 (2005-02-01), Frantz et al.
patent: 2005/0233960 (2005-10-01), Kong-Beltran et al.
patent: 2006/0263808 (2006-11-01), Yauch
patent: 2006/0270594 (2006-11-01), Kong-Beltran et al.
patent: WO 96/38557 (1996-12-01), None
patent: 97/38125 (1997-10-01), None
patent: WO 2004/072117 (2004-08-01), None
patent: WO 2005/016382 (2005-02-01), None
patent: WO 2005/063816 (2005-07-01), None
patent: 2006/104912 (2006-10-01), None
A. Peracchi et al, Rev. Med. Virol., 14: 47-64 (2004).
A. Branch, Trends in Biochem. Sci. 23: 45-50 (1998).
S. Crooke, Antisense Res. and Application, Chapter 1, pp. 1-50 (1998).
S.R. Hubbard, Nature Rev. Mol. Cell. Biol., vol. 5, pp. 464-471 (2004).
Opalinska et al, Nature Rev., 1: 503-514 (2004).
S. Agrawal et al., Molecular Med. Today, 6: 72-81 (2000).
Chirila et al., Biomaterials, 23: 321-342 (2002).
Peschard et al, Mol. Cell, vol. 8, pp. 995-1004 (2001).
“European Patent Office search” (Apr. 30, 2008).
“SGX Drug Discovery and Development [online] URL:http://www.sgxpharma.com/pipeline/documents/SGX—echeminfo—10172007—Final.pdf [retrieved on Mar. 28, 2008]”SGX Pharmaceuticalspp. 1-27 (Mar. 2008).
Dietrich, Sascha, et al., “Role of c-MET in Upper Aerodigestive Malignancies—From Biology to Novel Therapies”J. of Environmental Pathology, Toxicology and Oncology24(3):149-162 (2005).
Liu, Youhua, “The human hepatocyte growth factor receptor gene: complete structural organization and promoter characterization1”Gene215:159-169 (1998).
Lynch et al., “Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib”New England J. of Medicine350(21):2129-2139 (May 20, 2004).
Ma Patrick C. et al., “c-Met: Structure, functions and potential for therapeutic inhibition”Cancer and Metastasis Reviews22(4):309-325 (Dec. 2003).
NCBI, “Database NCBI [online] Accession No. rs35225896 Aug. 10, 2005”.
Paez et al., “EGFR Mutations in Lung Cancer, Correlation with Clinical Response to Gefitinib Therapy”Science304:1497-1500 (Jun. 4, 2004).
Pao et al., “EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib”Proc. Natl. Acad. Sci. USA101(36):13306-13311 (Sep. 7, 2004).
Serra et al., “Somatic NF1mutational spectrum in benign neurofibromas:mRNA splice defects are common among point mutations”Hum Genet108:416-429 (May 8, 2001).
Sordella et al., “Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways”Science305:1163-1167 (Aug. 20, 2004).
Tockman et al., “Considerations in Bringing a Cancer Biomarker to Clinical Application”Cancer Research52:2711s-2718s (May 1, 1992).
Baek et al., “Transforming variant of Met receptor confers serum independence and anti-apoptotic property and could be involved in the mouse thymic lymphomagenesis”Experimental and Molecular Medicine36(4):283-291 (Aug. 2004).
Bardelli et al., “Gabl Coupling to the HGF/Met Receptor Multifunctional Docking Site Requires Binding of Grb2 and Correlates with the Transforming Potential”Oncogene15:3103-3111 (1997).
Birchmeier et al., “Met, Metastasis, Motility and More”Nature Reviews Molecular Cell Biology4:915-925 (Dec. 2003).
Bladt et al., “Essential Role for the C-met Receptor in the Migration of Myogenic Precursor Cells into the Limb Bud”Nature376:768-770 (Aug. 31, 1995).
Boix et al., “C-Met mRNA Overexpression in Human Hepatocellular Carcimoma”Hepatology19(1):88-91 (Jan. 1994).
Bussolino et al., “Hepatocyte Growth Factor is a Potent Angiogenic Factor Which Stimulates Endothelial Cell Motility and Growth”Journal of Cell Biology119(3):629-641 (Nov. 1992).
Cooper et al., “Molecular cloning of a new transforming gene from a chemically transformed human cell line”Nature311:29-33 (Sep. 6, 1984).
Danilkovitch-Miagkova & Zbar, “Dysregulation of Met receptor tyrosine kinase activity in invasive tumors”The Journal of Clinical Investigation109(7):863-867 (Apr. 2002).
Di Renzo et al., “Overexpression and Amplification of the Met/HGF Receptor Gene During the Progression of Colorectal Cancer”Clinical Cancer Research1:147-154 (Feb. 1995).
Elliott et al., “The role of hepatocyte growth factor (scatter factor) in epithelial-mesenchymal transition and breast cancer”Can. J. Physiol. Pharmacol. 80:91-102 (Feb. 2002).
Furge et al., “Met Receptor Tyrosine Kinase: Enhanced Signaling Through Adapter Proteins”Oncogene19:5582-5589 (2000).
Gherardi et al., “Functional map and domain structure of MET, the product of the c-met protooncogene and receptor for hepatocyte growth factor/scatter factor”Proc. Natl. Acad. Sci. USA100(21):12039-12044 (Oct. 14, 2003).
Giordano et al., “Different Point Mutations in the MET Oncogene Elicit Distinct Biological Properties”The Faseb Journal14:399-406 (Feb. 2000).
Giordano et al., “The Semaphorin 4D Receptor Controls Invasive Growth by Coupling with MET”Nature Cell Biology4:720-724 (Sep. 2002).
Hartmann et al., “The Motility Signal of Scatter Factor/Hepatocyte Growth Factor Mediated Through the Receptor Tyrosine Kinase Met Requires Intracellular Action of Ras”Journal of Biological Chemistry269(35):21936-21939 (Sep. 2, 1994).
Heinrich et al., “PDGFRA activating mutations in gastrointestinal stromal tumors”Science299(5607):708-710 (Jan. 31, 2003).
Hirota et al., “Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors”Science279(5350):577-580 (Jan. 23, 1998).
Hubbard, “Juxtamembrane autoinhibition in receptor tyrosine kinases.”Nature Rev Mol Cell Bio. 5:464-470 (Jun. 2004).
Jeffers et al., “Activating Mutations for the Met Tyrosine Kinase Receptor in Human Cancer”Proc. Natl. Acad. Sci. USA94:11445-11450 (Oct. 1997).
Jeffers et al., “Degradation of the Met Tyrosine Kinase Receptor by the Ubiquitin-Proteasome Pathway”Molecular&Cellular Biology17(2):799-808 (Feb. 1997).
Jeffers et al., “Enhanced Tumorigenicity and Invasion-Metastasis by Hepatocyte Growth Factor/Scatter Factor-met Signaling in Human Cells Concomittant with Induction fo the Urokinase Proteolysis Network”Molecular&Cellular Biology16(3):1115-1125 (Mar. 1996).
Jin et al., “Expression of Scatter Factor and C-Met Receptor in Benign and Malignant Breast Tissue”Cancer79(4):749-760 (Feb. 15, 1997).
Kong-Beltran et al., “Somatic mutations lead to an oncogenic deletion of met in lung cancer”Cancer Research66(1):283-289 (Jan. 1, 2006).
Kong-Beltran M et al., “The Sema domain of Met is necessary for receptor dimerization and activation”Cancer Cell6(1):75-84 (Jul. 2004).
Kuniyasu et al., “Aberrant Expression of C-met mRNA in Human Gastric Carcinomas”Int. J. Cancer55:72-75 (1993).
Lee et al., “Identification of a Novel Type of Alternative Splicing of a Tyrosine Kinase Receptor”Journal of Biological Chemistry269(30):19457-19461 (Jul. 29, 1994).
Liu et al., “Overexpression of C-met Proto-Oncogene But Not Epidermal Growth Factor Receptor or C-erbB-2 in Primary Human Colorectal Carcinomas”Oncogene7:181-185 (1992).
Lorenzato et al., “Novel Somatic Mutations of the MET Oncogene in Human Carcinoma Metastases Activating Cell Motility and Invasion”Cancer Research62:7025-7030 (Dec. 1, 2002).
Ma et al., “c-MET Mutational Analysis in Small Cell Lung Cancer: Novel Juxtamembrane Domain Mutations

Affiliated with

Also associated with

Rating

Methods and compositions for modulating hyperstabilized c-met does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods and compositions for modulating hyperstabilized c-met, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for modulating hyperstabilized c-met will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4081422